BRPI0511917A - composto ou sais farmaceuticamente aceitáveis do mesmo, processo para preparar um composto, composição farmacêutica, método para tratar ou prevenir um distúrbio que requer a inibição do canal de potássio, e, uso de um composto - Google Patents

composto ou sais farmaceuticamente aceitáveis do mesmo, processo para preparar um composto, composição farmacêutica, método para tratar ou prevenir um distúrbio que requer a inibição do canal de potássio, e, uso de um composto

Info

Publication number
BRPI0511917A
BRPI0511917A BRPI0511917-0A BRPI0511917A BRPI0511917A BR PI0511917 A BRPI0511917 A BR PI0511917A BR PI0511917 A BRPI0511917 A BR PI0511917A BR PI0511917 A BRPI0511917 A BR PI0511917A
Authority
BR
Brazil
Prior art keywords
compound
alkyl
pharmaceutically acceptable
treating
preventing
Prior art date
Application number
BRPI0511917-0A
Other languages
English (en)
Portuguese (pt)
Inventor
John Ford
Nicholas John Palmer
John Frederick Atherall
David John Madge
Original Assignee
Xention Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0412986.2A external-priority patent/GB0412986D0/en
Application filed by Xention Discovery Ltd filed Critical Xention Discovery Ltd
Publication of BRPI0511917A publication Critical patent/BRPI0511917A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0511917-0A 2004-06-10 2005-06-10 composto ou sais farmaceuticamente aceitáveis do mesmo, processo para preparar um composto, composição farmacêutica, método para tratar ou prevenir um distúrbio que requer a inibição do canal de potássio, e, uso de um composto BRPI0511917A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57835004P 2004-06-10 2004-06-10
GBGB0412986.2A GB0412986D0 (en) 2004-06-10 2004-06-10 Compounds
PCT/GB2005/002318 WO2005121149A1 (en) 2004-06-10 2005-06-10 Furanopyrimidine compounds effective as potassium channel inhibitors

Publications (1)

Publication Number Publication Date
BRPI0511917A true BRPI0511917A (pt) 2008-01-15

Family

ID=35094157

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511917-0A BRPI0511917A (pt) 2004-06-10 2005-06-10 composto ou sais farmaceuticamente aceitáveis do mesmo, processo para preparar um composto, composição farmacêutica, método para tratar ou prevenir um distúrbio que requer a inibição do canal de potássio, e, uso de um composto

Country Status (8)

Country Link
EP (1) EP1758909A1 (ja)
JP (1) JP4955557B2 (ja)
KR (1) KR20070055486A (ja)
AU (1) AU2005252440A1 (ja)
BR (1) BRPI0511917A (ja)
CA (1) CA2568304A1 (ja)
MX (1) MXPA06014256A (ja)
WO (1) WO2005121149A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005061171A1 (de) 2005-12-21 2007-07-05 Bayer Healthcare Ag Neue, cyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung
DE102005061170A1 (de) * 2005-12-21 2007-07-05 Bayer Healthcare Ag Neue, acyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung
DE102007019690A1 (de) * 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007019691A1 (de) 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007027799A1 (de) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte Furopyrimidine und ihre Verwendung
DE102007027800A1 (de) * 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
DE102007054786A1 (de) 2007-11-16 2009-05-20 Bayer Healthcare Ag Trisubstituierte Furopyrimidine und ihre Verwendung
MY160243A (en) 2009-09-03 2017-02-28 Bristol Myers Squibb Co Quinazolines as potassium ion channel inhibitors
NO3175985T3 (ja) 2011-07-01 2018-04-28
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
US20150045305A1 (en) 2012-01-27 2015-02-12 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
WO2014134419A1 (en) 2013-03-01 2014-09-04 Gilead Sciences, Inc. Use of ikach blockers for the treatment of cardiac diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199584A (en) * 1977-05-27 1980-04-22 Imperial Chemical Industries Limited Pesticidal active furo[2,3-d] pyrimidine derivatives, compositions containing the same and use thereof
US5137879A (en) * 1990-03-30 1992-08-11 Dowelanco Furopyrimidin-4-imine derivatives
CA2341678C (en) * 1998-09-01 2009-10-13 Bristol-Myers Squibb Company Potassium channel inhibitors and method
EP1240147A1 (en) * 1999-12-21 2002-09-18 Icagen, Inc. Potassium channel inhibitors
DE10141212A1 (de) * 2001-08-22 2003-03-06 Bayer Ag Neue 4-Aminofuropyrimidine und ihre Verwendung

Also Published As

Publication number Publication date
MXPA06014256A (es) 2007-03-12
JP4955557B2 (ja) 2012-06-20
AU2005252440A1 (en) 2005-12-22
WO2005121149A1 (en) 2005-12-22
EP1758909A1 (en) 2007-03-07
CA2568304A1 (en) 2005-12-22
KR20070055486A (ko) 2007-05-30
JP2008501773A (ja) 2008-01-24

Similar Documents

Publication Publication Date Title
BRPI0511917A (pt) composto ou sais farmaceuticamente aceitáveis do mesmo, processo para preparar um composto, composição farmacêutica, método para tratar ou prevenir um distúrbio que requer a inibição do canal de potássio, e, uso de um composto
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
TW200720266A (en) Benzodioxane and benzodioxolan derivatives and uses thereof
BRPI0413152A (pt) derivados de benzimidazol alquilado por n3 como inibidores de mek
BRPI0519058A2 (pt) composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
NZ517696A (en) Biaryl ether derivatives useful as monoamine reuptake inhibitors
ECSP099394A (es) Derivados de quinuclidinol como antogonistas de receptores muscarínicos
PE20050089A1 (es) Derivados de azo [1,2-c] quinazolina condensados
BR9810829A (pt) Composto, processo para preparar o mesmo, composição, uso de um composto ou um sal farmaceuticamente aceitável do mesmo ou uma composição, e, processo de tratamento de uma condição
RS53523B1 (en) ANILINE-PYRIMIDINE DERIVATIVES WITH SUBSTITUTED SULFOXIMIN AS CDK INHIBITORS, THEIR PRODUCTION AND USE AS MEDICINES
AR061918A1 (es) Compuesto biciclico que contiene nitrogeno, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
TW200745117A (en) Macrocylic inhibitors of hepatitis C virus
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
PE20080611A1 (es) Compuestos de azabenzofuranil y metodos de uso
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
RS51044B (sr) 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-oni
BRPI0513932A (pt) derivados de indol-2-carboxamidina como antagonistas de receptores de nmda
CL2003002762A1 (es) Compuestos derivados de pirrolopirimidina o pirrolopiridina sustituidas por una amina ciclica, sus sales; composicion farmaceutica; y su uso para preparar un antagonista de los receptores de crf, para tratar enfermedades como depresion, ansiedad, alz
MY197875A (en) Cap-dependent endonuclease inhibitors
AR066111A1 (es) Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto
BRPI0416852A (pt) inibidores da quinase akt
AR050530A1 (es) Derivados de heteroaril sulfamida benzo-fusionada utiles como agentes anticonvulsivos
BR0207268A (pt) Quinazolinas como inibidores de mmp-13
TW200745061A (en) Macrocylic inhibitors of hepatitis C virus
BRPI0407699A (pt) Inibidores de rna-polimerase dependente de rna de vìrus de hepatite c e composições e tratamentos que os utilizam

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.